Roger Jeffs Sells 35,249 Shares of Liquidia (NASDAQ:LQDA) Stock

Posted by Shane Hupp on Jul 14th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 35,249 shares of Liquidia stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $2,520,655.99. Following the completion of the transaction, the chief executive officer owned 1,130,426 shares of the company’s stock, valued at approximately $80,836,763.26. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Jeffs also recently made the following trade(s):

On Wednesday, May 27th, Roger Jeffs sold 6,428 shares of Liquidia stock. The stock was sold at an average price of $62.18, for a total value of $399,693.04.
On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total transaction of $1,528,250.00.
On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $58.65, for a total transaction of $1,466,250.00.
On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total transaction of $1,426,000.00.
On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total transaction of $1,407,250.00.
On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00.
On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.

Liquidia Stock Up 7.4%

Liquidia stock traded up $5.28 during mid-day trading on Tuesday, hitting $76.49. The company had a trading volume of 1,153,916 shares, compared to its average volume of 2,219,263. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1 year low of $14.04 and a 1 year high of $82.96. The business has a fifty day moving average of $66.37 and a 200 day moving average of $47.52. The stock has a market cap of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, sell-side analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on LQDA. Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Wells Fargo & Company boosted their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Check Out Our Latest Stock Report on Liquidia

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the fourth quarter valued at approximately $25,000. Covestor Ltd lifted its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the period. FNY Investment Advisers LLC purchased a new position in Liquidia in the 3rd quarter valued at $34,000. NewEdge Advisors LLC purchased a new position in Liquidia in the 2nd quarter valued at $25,000. Finally, Fluent Financial LLC acquired a new position in Liquidia in the 2nd quarter valued at $287,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).